Toxicological Research

  • 제36권1호
  • /
  • Pages.21-27
  • /
  • 2020
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지
DOI QR코드

DOI QR Code

Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety

  • Afshari, Reza (Addiction Research Centre, Imam Reza (p) Hospital, Mashhad University of Medical Sciences) ;
  • Khadem-Rezaiyan, Majid (Clinical Research Development Unit, Faculty of Medicine, Mashhad University of Medical Sciences) ;
  • Moghadam, Hoda Khatibi (Department of Psychiatry, School of Medicine, Mashhad University of Medical Sciences) ;
  • Talebi, Mahdi (Department of Family Medicine, Mashhad University of Medical Sciences)
  • 투고 : 2018.11.05
  • 심사 : 2019.01.16
  • 발행 : 2020.01.15
⟨ 이전 논문 다음 논문 ⟩

초록

Withdrawal syndrome is one of the initial focuses of opioid detoxification. Very low dose naltrexone (VLNTX) has been found to reduce opioid tolerance and dependence in animal and human clinical studies. The aim of this study was to determine the safety and efficacy of VLNTX during early stages of detoxification. In a multi-arm parallel, double-blind, randomized controlled trial, 63 opioid-dependent male participants referring to Imam Reza Rehabilitation Center were allocated to three equal groups using block randomization method. They received 0.125 mg, 0.250 mg of VLNTX or placebo daily for 10 days, together with the routine clonidine-based protocol. Self-reported and observer ratings of withdrawal severity and adverse events were measured on the 1st, 4th and 10th day of treatment. Runny eyes (p = 0.006), anxiety (p = 0.031) and dehydration (p = 0.014) were reduced during the whole 10 days in the 0.125 mg VLNTX-treated group compared to placebo. Only drowsiness (p = 0.043) and dysphoric mood (p < 0.001) were reduced in the 0.250 mg VLNTX-treated group. Results of 1st, 4th, and 10th-day assessment showed that most symptoms reductions were for the 0.125 mg VLNTX and the placebo group in the 1st and 4th days, respectively. On the 10th day, there was not any significant difference between 0.250 mg VLNTX-treated group and placebo group. No adverse effect was observed. In the starting days of detoxification, VLNTX can reduce the withdrawal symptoms, but the efficacy declined by passing time. Further studies are needed to test the utility of this new therapeutic approach.

키워드

과제정보

We should appreciate the kind support of Deputy of Research at Mashhad University of Medical Sciences. This project is performed as the MD thesis of the first author (88725). The help of Dr. Malihe Dadgarmoghadam in English editing of the primary version of this manuscript is also appreciated.

참고문헌

  1. Afshari R, Shafaeeyan H, Afshari R (2006) An epidemiologic study of opioid dependent subjects who were volunteered for opioid detoxification in Iran, 2005. Clin Toxicol 44:581
  2. Iran Drug Control Headquarters (2014) Statistics of addiction in Iran. http://www.dchq.ir. Accessed Sept 2014
  3. Ghodse H, Myles J, Smith SE (1994) Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. Br J Psychiatry 165:370-374 https://doi.org/10.1192/bjp.165.3.370
  4. Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor C (1985) Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 42:391-394 https://doi.org/10.1001/archpsyc.1985.01790270081009
  5. Shen KF, Crain SM (1997) Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res 757:176-190 https://doi.org/10.1016/S0006-8993(97)00197-2
  6. Mannelli P, Patkar AA, Peindl K, Gorelick DA, Wu LT, Gottheil E (2009) Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol 14:204 https://doi.org/10.1111/j.1369-1600.2008.00119.x
  7. Mannelli P, Gottheil E, Peoples JF, Oropeza VC, Van Bockstaele EJ (2004) Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. Biol Psychiatry 56:261-268 https://doi.org/10.1016/j.biopsych.2004.05.013
  8. Gowing L, Ali R, White JM (2009) Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002021.pub4
  9. Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA (2012) The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. Am J Drug Alcohol Abuse 38:200-205 https://doi.org/10.3109/00952990.2011.644003
  10. Mannelli P, Patkar AA, Peindl K, Murray HW, Wu LT, Hubbard R (2007) Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. J Clin Psychopharmacol 27:468-474 https://doi.org/10.1097/jcp.0b013e31814e5e9d
  11. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63:210-218 https://doi.org/10.1001/archpsyc.63.2.210
  12. Javidi DB, Afshari R, Jalili SJ, Nazemian F (2009) Comparison of opioid induced withdrawal symptoms; post opioid overdose versus naltrexone interaction with opioids. In: Proceeding of 8th annual congress of the Asia pacific of medical toxicology 2009. Beijing, China, p 42
  13. Rea F, Bell JR, Young MR, Mattick RP (2004) A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend 75:79-88 https://doi.org/10.1016/j.drugalcdep.2004.02.003
  14. Mannelli P, Gottheil E, Buonanno A, Risio SD (2003) Use of very low-dose naltrexone during opiate detoxification. J Addict Dis 22:63-70
  15. Mannelli P, Patkar AA, Peindl K, Gottheil E, Wu LT, Gorelick DA (2009) Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict 18:109-116 https://doi.org/10.1080/10550490902772785
  16. Heydari A, Vafaee M, Afshari R, Balali-Mood M (2007) Naltrexone interaction with opiates in addicts; clinical findings and management. In: The 6th meeting of Asian Pacific association of medial toxicology 2007. Bangkok, Thailand, p 52
  17. Kleber HD (1985) Naltrexone. J Subst Abuse Treat 2:117-122 https://doi.org/10.1016/0740-5472(85)90036-4
  18. Lutz PE, Ayranci G, Chu-Sin-Chung P, Matifas A, Koebel P, Filliol D, Befort K, Ouagazzal AM, Kieffer BL (2014) Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence. Neuropsychopharmacology 39:2694 https://doi.org/10.1038/npp.2014.126
  19. Le Merrer J, Befort K, Gardon O, Filliol D, Darcq E, Dembele D, Becker JA, Kieffer BL (2012) Protracted abstinence from distinct drugs of abuse shows regulation of a common gene network. Addict Biol 17:1-12 https://doi.org/10.1111/j.1369-1600.2011.00365.x
  20. Fine PG, Portenoy RK (2004) A clinical guide to opioid analgesia. Healthcare information programs. McGraw Hill, New York, pp 35-45
  21. Freye E, Levy JV (2005) Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal. Addict Biol 10:131-137 https://doi.org/10.1080/13556210500123019
  22. Gothoni P, Ikola W (1985) Ethanol withdrawal tremor potentiates the tremorogenic action of nicotine. Med Biol 63:131-136
  23. Spahn V, Fischer O, Endres-Becker J, Schafer M, Stein C, Zollner C (2013) Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner. Pain 154:598-608 https://doi.org/10.1016/j.pain.2012.12.026
  24. Mori T, Komiya S, Uzawa N, Inoue K, Itoh T, Aoki S, Shibasaki M, Suzuki T (2013) Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence. Eur J Pharmacol 715:238-245 https://doi.org/10.1016/j.ejphar.2013.05.015
  25. Li T, Hou Y, Cao W, Yan CX, Chen T, Li SB (2010) Naloxone-precipitated withdrawal enhances ERK phosphorylation in prefrontal association cortex and accumbens nucleus of morphine-dependent mice. Neurosci Lett 468:348-352 https://doi.org/10.1016/j.neulet.2009.11.030
  26. Chen JC, Tao PL, Li JY, Wong CH, Huang EK (2003) Endomorphin-1 and-2 induce naloxone-precipitated withdrawal syndromes in rats. Peptides 24:477-481 https://doi.org/10.1016/S0196-9781(03)00078-0
  27. Freye E, Levy JV (2005) Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal. Addict Biol 10:131-137 https://doi.org/10.1080/13556210500123019
  28. Okamoto K, Tashiro A, Thompson R, Nishida Y, Bereiter DA (2012) Trigeminal interpolaris/caudalis transition neurons mediate reflex lacrimation evoked by bright light in the rat. Eur J Neurosci 36:3492-3499 https://doi.org/10.1111/j.1460-9568.2012.08272.x
  29. Biala G, Polak P, Michalak A, Kruk-Slomka M, Budzynska B (2014) Influence of calcium channel antagonists on nonsomatic signs of nicotine and D-amphetamine withdrawal in mice. Pharmacol Rep 66:212-222 https://doi.org/10.1016/j.pharep.2014.02.003
  30. Shen H, Mohammad A, Ramroop J, Smith SS (2013) A stress steroid triggers anxiety via increased expression of α4βδ GABA A receptors in methamphetamine dependence. Neuroscience 254:452-475 https://doi.org/10.1016/j.neuroscience.2013.08.033
  31. Kothari S, Kushwah A, Kothari D (2013) Involvement of opioid and monoaminergic pain pathways in Aegle marmelos induced analgesia in mice. Indian J Pharmacol 45:371 https://doi.org/10.4103/0253-7613.115020
  32. Shahlaee A, Farahanchi A, Javadi S, Delfan B, Dehpour AR (2013) Sucrose-induced analgesia in mice: role of nitric oxide and opioid receptor-mediated system. Indian J Pharmacol 45:593 https://doi.org/10.4103/0253-7613.121370
  33. Mannelli P, Wu LT, Peindl KS, Swartz MS, Woody GE (2014) Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend 138:83-88 https://doi.org/10.1016/j.drugalcdep.2014.02.002